Clarus Biologics Inc.
Developer of a virus-like particle (VLP) immunotherapy platform intended to act as a vaccine adjuvant. The company reports preclinical demonstration of enhanced antibody, T-cell and mucosal responses across multiple animal species, dose-sparing effects, and plans for clinical-grade manufacturing and Phase I evaluation. Mission stated as increasing availability of safe and effective prophylactic and therapeutic technologies.
Industries
Nr. of Employees
small (1-50)
Products
Mucosal virus-like particle adjuvant (VLP adjuvant)
An alphavirus-derived VLP developed to act as a non-specific innate-immune activator when co-administered with antigenic material, intended to increase antibody, T-cell and mucosal responses and reduce required antigen dose.
Mucosal virus-like particle adjuvant (VLP adjuvant)
An alphavirus-derived VLP developed to act as a non-specific innate-immune activator when co-administered with antigenic material, intended to increase antibody, T-cell and mucosal responses and reduce required antigen dose.
Services
Commercial partnerships and licensing arrangements to combine the VLP platform with external antigens or vaccines for development and commercialization.
Commercial partnerships and licensing arrangements to combine the VLP platform with external antigens or vaccines for development and commercialization.
Expertise Areas
- Vaccine adjuvant and VLP platform development
- Preclinical immunogenicity and challenge studies
- Mucosal immunity and systemic immunology
- cGMP biomanufacturing planning for clinical material
Key Technologies
- Virus-like particles (alphavirus-derived VLPs)
- Recombinant protein/subunit antigens
- Primary dendritic cell infection assays
- Animal challenge models (rodent and non-human primate)
News & Updates
Article describing a two-component vaccine strategy combining a non-specific VLP activator with pathogen-specific antigen to elicit broad adaptive immune responses and enable rapid pandemic response.
Company states its VLP adjuvant enjoys broad patent protection.
Reported successful preclinical studies across multiple species demonstrating elevated immune responses, increased protection upon challenge, and no significant safety signals attributable to the VLP in tested animals.
Article describing a two-component vaccine strategy combining a non-specific VLP activator with pathogen-specific antigen to elicit broad adaptive immune responses and enable rapid pandemic response.
Company states its VLP adjuvant enjoys broad patent protection.
Reported successful preclinical studies across multiple species demonstrating elevated immune responses, increased protection upon challenge, and no significant safety signals attributable to the VLP in tested animals.